| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2005;111:1487-1491.)
© 2005 American Heart Association, Inc.
Heart Failure |
From the Clinical Scholars Program, Division of Cardiology, North Shore University Hospital, Manhasset, NY (J.D.S.-B., H.A.S.), and Division of Cardiovascular Medicine, University of Michigan, Ann Arbor (K.D.A.).
Correspondence to Jonathan D. Sackner-Bernstein, MD, FACC, Clinical Scholars Program, Division of Cardiology, Cohen 1, North Shore University Hospital, 300 Community Dr, Manhasset, NY 11030. E-mail jonathansb{at}yahoo.com
Received August 13, 2004; revision received November 26, 2004; accepted January 11, 2005.
| Abstract |
|---|
|
|
|---|
Methods and Results Randomized clinical trials comparing nesiritide with either placebo or active control for ADHF were identified by electronic and manual searches and thorough review of US Food and Drug Administration files available via the website. Worsening renal function was defined as an increase in serum creatinine >0.5 mg/dL. Relative risk across all studies was determined by meta-analysis with Mantel-Haenszel fixed-effects models (RRMH). Risk of dialysis and medical intervention for worsening renal function were compared between therapies. Frequency of worsening renal function was determined from 5 randomized studies that included 1269 patients. Use of Food and Drug Administrationapproved doses of nesiritide (
0.03 µg · kg1 · min1) significantly increased the risk of worsening renal function compared with noninotrope-based control (RRMH, 1.52; 95% CI, 1.16 to 2.00; P=0.003) or any control therapy, including noninotrope- and inotrope-based therapies (RRMH, 1.54; 95% CI, 1.19 to 1.98; P=0.001). Even low-dose nesiritide (
0.015 µg · kg1 · min1) significantly increased risk (P=0.012 and P=0.006 compared with noninotrope- and inotrope-based controls, respectively), as did nesiritide administered at any dose up to 0.06 µg · kg1 · min1 (P=0.002 and P=0.001, respectively). There was no difference in the need for dialysis between therapies.
Conclusions Nesiritide significantly increases the risk of worsening renal function in patients with ADHF. Whether worsening renal function reflects hemodynamic effect or renal injury is unknown, but the prognostic importance of worsening renal function suggests the need for further investigation in appropriately powered clinical trials.
Key Words: heart failure kidney meta-analysis natriuretic peptides pharmacology
| Introduction |
|---|
|
|
|---|
See p 1459
Renal dysfunction is a strong correlate of long-term risk in cardiovascular medicine. The level of renal dysfunction, measured by serum creatinine,1012 glomerular filtration rate,13,14 or calculated creatinine clearance,1517 predicts outcome in patients with heart failure1317 and in those after infarction.10,18,19 In parallel with the prognostic importance of the presence of renal dysfunction, worsening renal function immediately after coronary bypass portends a worse prognosis,20,21 as is the case for worsening renal function in patients hospitalized for acutely decompensated heart failure,2225 with an increase in serum creatinine of just 0.1 mg/dL predictive of worsened outcome independently of baseline creatinine.25 Moreover, the relationship between even transient increases in creatinine and worse outcome has been demonstrated at levels of 0.3 to 0.5 mg/dL.2225
Therefore, to determine whether there is potential risk with nesiritide, we performed a meta-analysis of randomized, double-blind, controlled trials of nesiritide in patients with acutely decompensated heart failure to assess the risk of worsening renal function.
| Methods |
|---|
|
|
|---|
Selection
Trials were selected for this meta-analysis when they fulfilled each of the following characteristics: randomized, double-blind, parallel-group study on patients with acutely decompensated chronic heart failure and effect on serum creatinine reported.
Risk of Worsening Renal Function
Although several definitions of worsening renal function were recorded in the study reports, the one used consistently in each of these trials was an increase in serum creatinine (SCr) >0.5 mg/dL recorded at any time during the inpatient portion of the trial. The clinical trials performed to date with nesiritide do not permit formal determination of dose-related effects of the drug. To address the concerns that any differences detected could be due to use of inappropriately high doses or conversely that higher doses might minimize potential adverse effects by achieving maximal hemodynamic benefit, 6 separate comparisons were performed: (1) the FDA-approved doses for nesiritide infusion (
0.03 µg · kg1 · min1)31 and noninotrope-based control therapy (defined as control therapy that did not mandate use of positive inotropic agents), (2) FDA-approved doses of nesiritide and all control therapies (including trials that did and did not mandate use of positive inotropic agents in the control group), (3) low doses of nesiritide (
0.015 µg · kg1 · min1) and noninotrope-based controls, (4) low doses of nesiritide (
0.015 µg · kg1 · min1) and all control therapies, (5) all nesiritide doses (up to 0.06 µg · kg1 · min1) and noninotrope-based controls, and (6) all nesiritide doses (up to 0.06 µg · kg1 · min1) and all control therapies.
Studies were reviewed for the incidence of worsening renal function; the data were extracted by 2 authors (J.S.B. and H.A.S.) into spreadsheet format.
Intervention for Worsening Renal Function
The occurrence of renal failure requiring dialysis was reported in 3 studies, and the occurrence of renal failure requiring a medical intervention but not dialysis was reported in 2 studies (Table 1). The frequency of each was tabulated separately.
|
Statistical Analyses
Meta-analyses were performed to determine the risk ratios (RRs) for worsening renal function (for each of the previously defined datasets), dialysis, and medical intervention without dialysis for nesiritide versus control therapy. For each analysis, data were assessed for interstudy heterogeneity by the Breslow-Day test.32 Because there was no evidence of heterogeneity, fixed-effects models were obtained with the Mantel-Haenszel technique (PROC FREQ, SAS for Macintosh, version 6.12, SAS Inc), with results expressed as adjusted RRs (RRMH) with 95% CIs. Two-tailed values of P<0.05 were considered significant without adjustments for multiple hypothesis testing.
| Results |
|---|
|
|
|---|
0.1), all meta-analyses were performed with fixed-effects models.
|
The incidence of worsening renal function requiring medical intervention was reported in 2 of the phase II infusion trials (studies 325 and 326), as was the need for dialysis, which was also reported in VMAC (Table 3).
|
Risk of Worsening Renal Function
Compared with noninotrope-based control therapy (ie, diuretics and other vasodilators), use of FDA-approved doses of nesiritide (
0.03 µg · kg1 · min1) in patients with acutely decompensated heart failure significantly increased the risk of worsening renal function (22% versus 15%; RRMH,1.52; 95% CI, 1.16 to 2.00; P=0.003), as did low-dose nesiritide (
0.015 µg · kg1 · min1; 23% versus 15%; RRMH, 1.46; 95% CI, 1.09 to 1.95; P=0.012) and nesiritide administered at any dose (
0.06 µg · kg1 · min1; 22% versus 15%; RRMH, 1.53; 95% CI, 1.16 to 2.00; P=0.002).
Compared with any control therapy, both noninotrope- and inotrope-based, nesiritide administered at FDA-approved doses, at low doses, or at any dose increased the risk of worsening renal function (21% versus 15% for each; RRMH,1.54; 95% CI, 1.19 to 1.98; P=0.001; RRMH, 1.47; 95% CI, 1.12 to 1.93; P=0.006; and RRMH, 1.54; 95% CI, 1.20 to 1.99; P=0.001, respectively; Table 4 and the Figure).
|
|
Intervention for Worsening Renal Function
The frequency of worsening renal function requiring medical intervention short of dialysis was increased in nesiritide-treated patients. As determined by the investigators, 32 of 288 nesiritide patients (11.1%) compared with 6 of 144 (4.2%) required medical intervention. This represented a statistically significant excess risk of 129% for the nesiritide group (RRMH, 2.29; 95% CI, 1.07 to 4.89; P=0.03).
There was, however, no difference between nesiritide and control groups in the need for dialysis, which was instituted in 14 of 561 nesiritide patients (2.5%) and 8 of 360 control patients (2.2%). The adjusted RRMH for nesiritide compared with control patients was 1.18 (95% CI, 0.50 to 2.76; P=0.71).
| Discussion |
|---|
|
|
|---|
During treatment of patients with acutely decompensated heart failure, serum creatinine levels can be quite dynamic. Krumholz et al22 reported that 28% (469 of 1681) of patients developed worsening renal function during heart failure hospitalization, which they defined as an increase in serum creatinine of
0.3 mg/dL. Patients with worsening renal function were at increased risk of death while hospitalized and within 30 days and 6 months of discharge [odds ratio (OR), 2.72; 95% CI, 1.62 to 4.58; OR, 1.87; 95% CI, 1.25 to 2.80; and OR, 1.56; 95% CI, 1.19 to 2.05, respectively]. Using similar definitions, Forman et al34 reported similar risks during the index hospitalization (RRMH, 7.5; 95% CI, 2.9 to 19.3). Although no threshold has been defined below which risk does not appear to be affected, as the magnitude of the change increases, so does the magnitude of the risk and the statistical robustness of the association.24,25 Larger increases in creatinine (
0.5 mg/dL) portend a worse prognosis, with a significantly increased risk of death (hazard ratio, 2.86; 95% CI, 1.55 to 5.26)24 predicted with high specificity (82%).25 In each of these studies, the changes in creatinine were assessed as peak levels, not the level that was eventually reached.
An acknowledged limitation to meta-analyses is the inability to adjust statistically for differences in other factors beyond treatment group assignment that could have influenced the development of renal dysfunction. Access to raw data might permit further risk adjustment by meta-regression techniques. Appropriately powered prospective studies could delineate whether the risk of worsening renal function is caused by nesiritide or is related to baseline characteristics in a subset of patients and could identify predictors of this phenomenon.
Despite the strength of the observation that worsening renal function is associated with worse clinical outcomes, no data in these or other studies demonstrate that this relationship is true for nesiritide as it is for some other therapies. The physiology of antagonizing the renin-angiotensin system appears to be an exception in which the relationship does not hold between transient worsening renal function and adverse outcome. Antagonizing angiotensin IIinduced efferent arteriolar vasoconstriction reduces glomerular filtration rate and generally leads to increases in creatinine levels.35 In fact, increased creatinine is a barometer that reflects adequacy of renin-angiotensin system blockade. Although it is possible that nesiritide could lead to worsening renal function without adversely affecting outcomes, this can be determined only by a prospective mortality trial. Furthermore, even if the basis for elevated creatinine levels were hemodynamic, it would not obviate the need for further investigation because both calcium channel blockers and nonsteroidal antiinflammatory drugs can worsen renal function in patients with acutely decompensated heart failure, in part by hemodynamic effects.23
Nesiritide is widely used, largely because of its prompt improvement of pulmonary capillary wedge pressure and symptoms.14 However, this should be balanced against the possibility of worsening renal function, especially in the absence of a long-term outcomes trial. The strong association between elevations in serum creatinine levels and risk reported by several studies,2225 coupled with the statistically significant risk of worsening renal function and the need for medical intervention with nesiritide therapy, suggests that nesiritide could be associated with clinically relevant risk. The presence of such an association suggests that the short-term effects of nesiritide may not be sufficient to ensure long-term safety. A prospective mortality trial is necessary to determine the proper use of nesiritide for patients with acutely decompensated heart failure.
| Acknowledgments |
|---|
| References |
|---|
|
|
|---|
65 years of age with heart failure. Am J Cardiol. 2000; 85: 11101113.[CrossRef][Medline]
[Order article via Infotrieve]This article has been cited by other articles:
![]() |
W. Mullens, Z. Abrahams, G. S. Francis, H. N. Skouri, R. C. Starling, J. B. Young, D. O. Taylor, and W.H. W. Tang Sodium nitroprusside for advanced low-output heart failure. J. Am. Coll. Cardiol., July 15, 2008; 52(3): 200 - 207. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. W. Yancy Vasodilator therapy for decompensated heart failure. J. Am. Coll. Cardiol., July 15, 2008; 52(3): 208 - 210. [Full Text] [PDF] |
||||
![]() |
O. Lisy, B. K. Huntley, D. J. McCormick, P. A. Kurlansky, and J. C. Burnett Jr Design, Synthesis, and Actions of a Novel Chimeric Natriuretic Peptide: CD-NP. J. Am. Coll. Cardiol., July 1, 2008; 52(1): 60 - 68. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Mrkobrada, H. Thiessen-Philbrook, R. B. Haynes, A. V. Iansavichus, F. Rehman, and A. X. Garg Need for Quality Improvement in Renal Systematic Reviews Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 1102 - 1114. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Burnett Jr and J. Korinek The Tumultuous Journey of Nesiritide: Past, Present, and Future Circ Heart Fail, May 1, 2008; 1(1): 6 - 8. [Full Text] [PDF] |
||||
![]() |
C. W. Yancy, H. Krum, B. M. Massie, M. A. Silver, L. W. Stevenson, M. Cheng, S. S. Kim, R. Evans, and for the FUSION II Investigators Safety and Efficacy of Outpatient Nesiritide in Patients With Advanced Heart Failure: Results of the Second Follow-Up Serial Infusions of Nesiritide (FUSION II) Trial Circ Heart Fail, May 1, 2008; 1(1): 9 - 16. [Abstract] [Full Text] [PDF] |
||||
![]() |
R J Hillock, C M Frampton, T G Yandle, R W Troughton, J G Lainchbury, and A M Richards B-type natriuretic peptide infusions in acute myocardial infarction Heart, May 1, 2008; 94(5): 617 - 622. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. S. Pang, J. G.F. Cleland, J. R. Teerlink, S. P. Collins, C. J. Lindsell, G. Sopko, W. F. Peacock, G. C. Fonarow, A. Z. Aldeen, J. D. Kirk, et al. A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach Eur. Heart J., March 2, 2008; 29(6): 816 - 824. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Herget-Rosenthal, F. Saner, and L. S. Chawla Approach to Hemodynamic Shock and Vasopressors Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(2): 546 - 553. [Full Text] [PDF] |
||||
![]() |
R. J DiDomenico, A. Perez, H. M Schumann, D. R Fontana, G. T Kondos, and G. T Schumock Impact of Treatment Guidelines on Clinical and Economic Outcomes of Acute Decompensated Heart Failure Ann. Pharmacother., March 1, 2008; 42(3): 327 - 333. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kazory and E. A. Ross Contemporary Trends in the Pharmacological and Extracorporeal Management of Heart Failure: A Nephrologic Perspective Circulation, February 19, 2008; 117(7): 975 - 983. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Mullens, Z. Abrahams, H. N. Skouri, G. S. Francis, D. O. Taylor, R. C. Starling, E. Paganini, and W.H. W. Tang Elevated Intra-Abdominal Pressure in Acute Decompensated Heart Failure: A Potential Contributor to Worsening Renal Function? J. Am. Coll. Cardiol., January 22, 2008; 51(3): 300 - 306. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. I. Iglesias, L. DePalma, D. Hom, M. Antoniotti, S. Ayoub, and J. S. Levine Predictors of mortality in adult patients with congestive heart failure receiving nesiritide Retrospective analysis showing a potential adverse interaction between neseritide and acute renal dysfunction Nephrol. Dial. Transplant., January 1, 2008; 23(1): 144 - 153. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. V. McMurray, J. R. Teerlink, G. Cotter, R. C. Bourge, J. G. F. Cleland, G. Jondeau, H. Krum, M. Metra, C. M. O'Connor, J. D. Parker, et al. Effects of Tezosentan on Symptoms and Clinical Outcomes in Patients With Acute Heart Failure: The VERITAS Randomized Controlled Trials JAMA, November 7, 2007; 298(17): 2009 - 2019. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Silver and C. W. Yancy Using Homeostatic Peptides in Decompensated Heart Failure: A Reasonable Paradigm But a Flawed Practice? J. Am. Coll. Cardiol., November 6, 2007; 50(19): 1841 - 1843. [Full Text] [PDF] |
||||
![]() |
R. M. Witteles, D. Kao, D. Christopherson, K. Matsuda, R. H. Vagelos, D. Schreiber, and M. B. Fowler Impact of Nesiritide on Renal Function in Patients With Acute Decompensated Heart Failure and Pre-Existing Renal Dysfunction: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial J. Am. Coll. Cardiol., November 6, 2007; 50(19): 1835 - 1840. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Arora, K. Clarke, V. Srinivasan, and A. Gradman Effect of nesiritide on renal function in patients admitted for decompensated heart failure QJM, November 1, 2007; 100(11): 699 - 706. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. L. Martin, T. Supaporn, H. H. Chen, S. M. Sandberg, Y. Matsuda, M. Jougasaki, and J. C. Burnett Jr. Distinct roles for renal particulate and soluble guanylyl cyclases in preserving renal function in experimental acute heart failure Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2007; 293(4): R1580 - R1585. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. R. Schwarz, S. Najam, R. Akel, N. Sulimanjee, S. Bionat, and S. Rosanio Intermittent Outpatient Nesiritide Infusion Reduces Hospital Admissions in Patients With Advanced Heart Failure Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2007; 12(3): 232 - 236. [Abstract] [PDF] |
||||
![]() |
V. Vats, R. J DiDomenico, J. E Wojtynek, J. C Theobald, and G. T Schumock Hospital Policies for Treatment of Acute Decompensated Heart Failure Ann. Pharmacother., April 1, 2007; 41(4): 562 - 567. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L Chow, J. T Peng, M. P Okamoto, and J T. Heywood Effect of Nesiritide Infusion Duration on Renal Function in Acutely Decompensated Heart Failure Patients Ann. Pharmacother., April 1, 2007; 41(4): 556 - 561. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Konstam, M. Gheorghiade, J. C. Burnett Jr, L. Grinfeld, A. P. Maggioni, K. Swedberg, J. E. Udelson, F. Zannad, T. Cook, J. Ouyang, et al. Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure: The EVEREST Outcome Trial JAMA, March 28, 2007; 297(12): 1319 - 1331. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Gheorghiade, M. A. Konstam, J. C. Burnett Jr, L. Grinfeld, A. P. Maggioni, K. Swedberg, J. E. Udelson, F. Zannad, T. Cook, J. Ouyang, et al. Short-term Clinical Effects of Tolvaptan, an Oral Vasopressin Antagonist, in Patients Hospitalized for Heart Failure: The EVEREST Clinical Status Trials JAMA, March 28, 2007; 297(12): 1332 - 1343. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. R. Forfia, M. Lee, R. S. Tunin, M. Mahmud, H. C. Champion, and D. A. Kass Acute Phosphodiesterase 5 Inhibition Mimics Hemodynamic Effects of B-Type Natriuretic Peptide and Potentiates B-Type Natriuretic Peptide Effects in Failing But Not Normal Canine Heart J. Am. Coll. Cardiol., March 13, 2007; 49(10): 1079 - 1088. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Kesselheim and M. M. Mello Confidentiality Laws And Secrecy In Medical Research: Improving Public Access To Data On Drug Safety Health Aff., March 1, 2007; 26(2): 483 - 491. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Belenkie Nesiritide Administration in Patients With Left Ventricular Dysfunction Undergoing Coronary Artery Bypass Surgery J. Am. Coll. Cardiol., February 13, 2007; 49(6): 727 - 728. [Full Text] [PDF] |
||||
![]() |
R. M. Mentzer Jr, M. C. Oz, R. N. Sladen, A. H. Graeve, R. F. Hebeler Jr, J. M. Luber Jr, N. G. Smedira, and on behalf of the NAPA Investigators Effects of Perioperative Nesiritide in Patients With Left Ventricular Dysfunction Undergoing Cardiac Surgery: The NAPA Trial J. Am. Coll. Cardiol., February 13, 2007; 49(6): 716 - 726. [Abstract] [Full Text] [PDF] |
||||
![]() |
|